Jiangsu Recbio Technology and Shenzhen Rhegen Biotechnology have recently signed a joint venture agreement to establish a joint venture company "Wuhan Rhecogen Biotechnology Co., Ltd.", to integrate the advantages of both parties and focus on deep and extensive cooperation in the field of mRNA vaccine R&D and industrialization.

This cooperation is a measure taken by the two Chinese firms to implement the earlier agreement on strategic partnership in mRNA vaccines.

The joint venture company will be landed in Guanggu, Wuhan, and its holding company is Recbio. The joint venture company will use the mRNA technology and novel adjuvant technology to develop a new generation of COVID-19 vaccines and plan to gradually develop other major infectious disease vaccines and tumor therapeutic vaccines.

The establishment of the joint venture company will integrate advantages of both Recbio and Rhegen Bio with an potential to become an innovative vaccine company with international competitiveness.